This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2011, the Jeopardy!-winning winning supercomputer was announced as a new tool for doctors and researchers, capable of analyzing massive amounts of data to help diagnose diseases, develop new treatments, and improve patient care. Clinical Development: Clinical Trial Matching: Matches patients to appropriate clinical trials.
In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugsdeveloped to treat Type 2 diabetes. In 2011 he published a paper on liraglutide , marketed by Novo Nordisk under the brand names Victoza. Research & studies.
SGLT2 Development and Method of Action. Ever since the first SGLT2 inhibitor (dapagliflozin) was approved by the EU in 2011 and the USA in 2014, it and another nine gliflozin drugsdeveloped since then have been considered for (off-label) use in Type-1 diabetes, as well as in Type-2 diabetes for which they were first approved.
Could this mean that there will be a streamlined pipeline for diabetes drugdevelopment? According to a 2011 law review of presidential authority, presidents can propose streamlined regulations, but agencies still must go through a public process to establish the harm vs. benefit of changed regulations. It’s unclear.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content